AstraZeneca Secures EU’s Approval for Fixed-Duration Calquence-Based Regimens in First-Line Chronic Lymphocytic Leukemia (CLL)
AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.
